FOLD earnings call for the period ending March 31, 2019.
News & Analysis: Amicus Therapeutics
These growth companies could make a killing if their big bets pay off.
FOLD earnings call for the period ending December 31, 2018.
Amicus' shares crumbled with the broader market's decline last month, but the biotech has staged a stunning rally during the first few weeks of trading in 2019.
The company is expanding its pipeline of gene therapies.
A new treatment of Fabry disease could be available in the United States as soon as 2018.
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Amicus' stock continues to benefit from its emerging rare disease pipeline and the industrywide upswing in biotech valuations this year.
The Food and Drug Administration changed its tune on Amicus' lead drug, and shareholders couldn't be happier.
After an about-face at the FDA sent shares soaring earlier this week, management announced a stock offering to bolster its balance sheet.